Cancer Genetics Inc.

4.61-0.1100-2.33%Vol 612.40K1Y Perf 49.68%
Mar 30th, 2021 16:00 DELAYED
BID4.60 ASK4.75
Open4.67 Previous Close4.72
Pre-Market- After-Market-
 - -  - -%
Target Price
4.50 
Analyst Rating
Hold 3.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     34.68
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
+     26.43
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap18.83M 
Earnings Rating
Buy
Price Range Ratio 52W %
16.24 
Earnings Date
18th Nov 2020

Today's Price Range

4.304.69

52W Range

2.1117.50

5 Year PE Ratio Range

-1.30-0.6000

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
0.00%
1 Month
-26.36%
3 Months
45.89%
6 Months
5.25%
1 Year
49.68%
3 Years
-84.16%
5 Years
-94.24%
10 Years
-

TickerPriceChg.Chg.%
CGIX4.61-0.1100-2.33
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
0.40
0.60
0.02
0.04
-9.70
Leverage Ratio 2.20
ProfitabilityValueIndustryS&P 500US Markets
47.30
-60.30
-46.50
-36.90
-95.32
RevenueValueIndustryS&P 500US Markets
4.44M
0.42
-41.66
-18.76
Earnings HistoryEstimateReportedSurprise %
Q03 2020--0.58-
Q02 2020--0.82-
Q01 2020--0.56-
Q04 2019--0.14-
Q03 2019--0.32-
Q02 2019--0.01-
Q01 2019--0.08-
Q04 2018--0.14-
Earnings Per EndEstimateRevision %Trend
3/2019 QR-0.070.00-
6/2019 QR-0.050.00-
12/2019 FY-0.110.00-
12/2019 FY-0.11--
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume612.40K
Shares Outstanding4.09M
Trades Count3.10K
Dollar Volume28.34M
Avg. Volume2.44M
Avg. Weekly Volume2.30M
Avg. Monthly Volume1.14M
Avg. Quarterly Volume2.33M

Cancer Genetics Inc. (NASDAQ: CGIX) stock closed at 4.61 per share at the end of the most recent trading day (a -2.33% change compared to the prior day closing price) with a volume of 612.40K shares and market capitalization of 18.83M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 35 people. Cancer Genetics Inc. CEO is John A. Roberts.

The one-year performance of Cancer Genetics Inc. stock is 49.68%, while year-to-date (YTD) performance is 66.43%. CGIX stock has a five-year performance of -94.24%. Its 52-week range is between 2.11 and 17.5, which gives CGIX stock a 52-week price range ratio of 16.24%

Cancer Genetics Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 10.13, a price-to-sale (PS) ratio of 11.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -28.19%, a ROC of -56.97% and a ROE of -70.51%. The company’s profit margin is -95.32%, its EBITDA margin is -46.50%, and its revenue ttm is $4.44 Million , which makes it $0.42 revenue per share.

Of the last four earnings reports from Cancer Genetics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cancer Genetics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cancer Genetics Inc. is Hold (3), with a target price of $4.5, which is 0.00% compared to the current price. The earnings rating for Cancer Genetics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cancer Genetics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cancer Genetics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 42.02, ATR14 : 0.88, CCI20 : -60.38, Chaikin Money Flow : -0.35, MACD : 0.07, Money Flow Index : 54.97, ROC : -13.99, RSI : 53.35, STOCH (14,3) : 10.51, STOCH RSI : 0.95, UO : 64.74, Williams %R : -89.49), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cancer Genetics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

Cancer Genetics Inc.

Cancer Genetics Inc through its vivoPharm subsidiary offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The company is focused on precision and translational medicine to drive drug discovery and novel therapies. Its subsidiary, vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. VivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.

CEO: John A. Roberts

Telephone: 201 479-1357

Address: 201 Route 17 North, Rutherford 07070, NJ, US

Number of employees: 35

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

52%48%

Bearish Bullish

54%46%

News

Stocktwits